Skip to main content
Signal8

Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results

$PLXPress releaseNov 10, 2026, 6:45 AM ETRead the release

Protalix reported Q3 2026 revenue of $21.9 million, up ~23% year-over-year, with net income of $4.0 million ($0.05 per share) versus $2.4 million a year ago. Year-to-date revenue reached $75.6 million versus $43.6 million, driven largely by a $25.0 million Chiesi milestone tied to the EU approval of Elfabrio's every-four-weeks dosing; goods revenue also rose on higher Chiesi sales, partially offset by lower Pfizer and Fiocruz purchases. Management reaffirmed 2026 guidance of $78-83 million in total revenues and said it expects to meet or exceed the range, ending September with $48.5 million in cash and deposits and no debt or warrants.

Key figures

Eps
0.05
Revenue
75571000
Guidance
2026 total revenues of approximately $78.0 million to $83.0 million, expects to meet or exceed; Elfabrio ex-milestone ~$33.0-35.0M; Elelyso ~$20.0-23.0M
Revenue Yoy
73% (YTD, boosted by $25M milestone; Q3 $21.9M vs $17.9M, +23%)
Q3 revenue
21925000
Eps ytd basic
0.33
Net income q3
3961000
Net income ytd
26055000
Operating income ytd
29865000
Q3 revenue prior year
17851000
Chiesi milestone q1 2026
25000000
Net income q3 prior year
2355000
Cash and short term deposits
48500000

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    PLX: Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results — AI Analysis | Signal8